CRISPR screen identifies genes that sensitize AML cells to double negative T cell therapy [RNA-Seq]

Here, we used a targeted CRISPR/Cas9 screen to identify genes that confer susceptibility of AML cells to DNT cell therapy. Overall design: Total RNA was extracted from AML3 cells using the RNeasy Plus Mini Kit (Qiagen Cat. 74314) following manufacture's guidelines. On column DNase I digestion was performed for 15 mins at room temperature and RNA purity was assessed by Nanodrop (260/280, > 2.0). RNA-seq libraries were prepared using the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian (634418, Takara). Libraries were verified using TapeStation (Tape 2200, Agilent Technologies) and 150-bp paired-end sequencing was performed